NEW YORK, April 11, 2018 /PRNewswire/ -- WeissLaw LLP
is investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of AveXis Inc. ("AVXS"
or the "Company") (NASDAQ: AVXS) in connection with the proposed
acquisition of the Company by Novartis AG ("Novartis"). Under
the terms of the acquisition agreement, the Company's shareholders
will receive $218.00 in cash for each
AVXS share they own.
WeissLaw is investigating whether AVXS's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, the deal is a strategic transaction which will
catapult Novartis into leadership in the field of gene therapy and
neuroscience, granting Novartis access to AVXS' gene therapy
pipeline and the Company's portfolio of gene therapy
treatments.
Given these facts, WeissLaw is investigating whether AVXS's
Board acted in the best interests of AVXS's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own AVXS shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the form
on our website, http://www.weisslawllp.com/avexis-inc/
View original
content:http://www.prnewswire.com/news-releases/weisslaw-llp-investigates-avexis-inc-acquisition-300628547.html
SOURCE WeissLaw LLP